Historically, clinical supply teams aimed to guarantee the availability of study materials at trial sites. However, contemporary shifts in trial design, including hybrid and decentralized models, have underscored the importance of directly delivering investigational products to patients' residences.
Signant's RTSM solution empowers direct-to-patient clinical supply distributions, yielding advantages for all involved parties:
- Alleviates patient and site responsibilities
- Ensures comprehensive traceability
- Enhances workflow efficiency
For deeper insights, refer to the informative brochure below.